Freenome — Third Quarter 2026 Earnings Summary

Freenome reported third-quarter 2026 total revenue of $183.5 million, a significant increase from $1.0 million in the same period of 2025, driven primarily by a $180 million milestone payment following FDA approval of its SimpleScreen CRC test. The company achieved a GAAP net income of $60.1 million for the quarter, contrasting with a net loss of $64.5 million in the prior year, while generating $38.4 million in net cash provided by operating activities. Following its public listing in July 2026, Freenome raised approximately $310 million in gross proceeds and holds $430 million in cash, cash equivalents, and marketable securities as of September 30, 2026. The company has launched SimpleScreen CRC commercially in the United States and expanded its portfolio with the introduction of SimpleScreen Lung, while providing full-year 2026 revenue guidance between $192 million and $194 million.